HBV mutation literature information.


  High frequency of lamivudine resistance mutations in Brazilian patients co-infected with HIV and hepatitis B.
 PMID: 20648600       2010       Journal of medical virology
Abstract: Mutations in the BCP region (A1762T, G1764A) and in the precore region (G1896A, G1899A) were also found.


  HBV mutations in untreated HIV-HBV co-infection using genomic length sequencing.
 PMID: 20655563       2010       Virology
Introduction: A Precore stop codon substitution at amino acid (aa) 28 (W28 stop, nucleotide (nt) G1896A) is associated with failure to synthesize hepatitis B e antigen (HBeAg).
Result: The proportions of G1896A, pol rt M204V, pol rt L180M or PreS1 deletions were similar in both mono and co-infected patients.
Result: We examined the frequency of the following mutations in the HBV genomes of the mono-infected and co-infected patients: Table: G1896A


  Hepatitis B virus-DNA level and basal core promoter A1762T/G1764A mutation in liver tissue independently predict postoperative survival in hepatocellular carcinoma.
 PMID: 20814897       2010       Hepatology (Baltimore, Md.)
Abstract: Assayed factors included the amount of HBV-DNA in the liver tissues; genotype; and the presence of the HBV precore stop codon G1896A mutation, basal core promoter A1762T/G1764A mutation, and pre-S deletions/stop codon mutation.


  Prevalent HBV point mutations and mutation combinations at BCP/preC region and their association with liver disease progression.
 PMID: 20846420       2010       BMC infectious diseases
Abstract: G1896A mutation appears to be independent of infection history.
Abstract: G1896A mutation seemed to be involved in liver disease progression independent of the patient age (OR = 3.6, 95% CI: 1.5-8.6; P = 0.004).
Abstract: The top three multi-mutations were A1762T/G1764A (36%), A1762T/G1764A/G1896A (11%) and T1753(A/C)/A1762T/G1764A/G1896A (8%).


  A case-control study on sequence variations in the enhancer II/core promoter/precore and X genes of hepatitis B virus in patients with hepatocellular carcinoma.
 PMID: 21063480       2010       Hepatology international
Abstract: No significant difference between groups was found with respect to G1613A, C1653T, C1766T/T1768A, A1846T/C, T1858C, and G1896A mutations.


  Prevalence and clinical significance of hepatitis B Basal core promoter and precore gene mutations in southern Iranian patients.
 PMID: 22312396       2010       Hepatitis monthly
Abstract: Fourteen of the 44 patients (31.8%) had mutations in the precore region (G 1896A).
Result: All of these 14 patients had mutations at the same position (G 1896A).
Result: Class 1 included 3 patients (6.8%) with a PC mutation at (G1896A) and a BCP mutation at (A1762/A1764).


  Prevalence and virological features of occult hepatitis B virus infection in female sex workers who work uncontrolled in Turkey.
 PMID: 18662283       2009       Liver international
Abstract: One PC (G1896A) and one BCP (T1762/A1764) mutation was found, but S gene mutation was not detected in any of the samples.


  Prevalence of basal core promoter and precore mutations in Chinese chronic hepatitis B patients and correlation with serum HBeAG titers.
 PMID: 19319958       2009       Journal of medical virology
Abstract: The A1762T and G1764A mutations in the basal core promoter (BCP) region and the G1896A mutation in the precore (PC) region of hepatitis B virus (HBV) genome are found commonly in HBeAg-negative patients.
Introduction: The most common PC mutation is a G to A transition at nucleotide (nt) 1896 (A1896) that creates a premature stop codon and abolishes HBeAg translation.
Discussion: The reason why patients harboring the G1896A precore mutation continued to express


  Frequent detection of hepatitis B virus variants associated with lamivudine resistance in treated South African patients infected chronically with different HBV genotypes.
 PMID: 19382250       2009       Journal of medical virology
Abstract: Of the 17 patients, 3 carried both pre-C (G1896A) and BCP (A1762T/G1764A) mutants, 1 pre-C only and 1 BCP only.


  Association of baseline viral factors with response to lamivudine therapy in chronic hepatitis B patients with high serum alanine aminotransferase levels.
 PMID: 19430095       2009       Antiviral therapy
Abstract: RESULTS: The frequency of patients with detectable PC stop codon mutation (G1896A), basal core promoter mutation (A1762T/G1764A) and pre-S deletion at baseline was 22.4%, 21.6% and 12.1%, respectively.



Browser Board

 Co-occurred Entities




   Filtrator